We are live on
!
Find out more
CA
CHI Advisors Portfolio holdings
AUM
$252M
1-Year Est. Return
56.99%
This Fund
S&P 500
This Quarter
Est. Return
-4.46%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$262M
AUM Growth
+$26.7M
(+11%)
Cap. Flow
+$49.5M
Cap. Flow
% of AUM
18.91%
Top 10 Holdings %
Top 10 Hldgs %
82.76%
Holding
28
New
6
Increased
13
Reduced
2
Closed
–
Avg Time Held Equity + Options
5.3
quarters
Top 10 Avg Time Held Equity + Options
3.2
quarters
Top 20 Avg Time Held Equity + Options
5.8
quarters
Avg Time Held Equity only
5.9
quarters
Top 10 Avg Time Held Equity only
3.2
quarters
Top 20 Avg Time Held Equity only
5.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kezar Life Sciences
KZR
|
+$13.5M |
| 2 |
Inozyme Pharma
INZY
|
+$4.97M |
| 3 |
Nkarta
NKTX
|
+$4.7M |
| 4 |
Precision BioSciences
DTIL
|
+$4.69M |
| 5 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$3.76M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONCR
Oncorus, Inc.
ONCR
|
+$67.9K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.85% |
| 2 | Miscellaneous | 0.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.71B
| $372K | 0.14% |
157,000
-65,500
| -29% | -$4.92M |
2022 Q1
1 quarter
|
|
|
27
CALL
DELISTED
Kezar Life Sciences
KZR
| $5K | ﹤0.01% |
+10,000
| New | +$882K |
2022 Q2
0 quarters
|
|
|
EIGR
28
CALL
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $4K | ﹤0.01% |
+837
| New | +$169K |
2022 Q2
0 quarters
|
|
Similar funds
SC
T
W
RBGI
TOGEPT
IAM
RCGI
AEPLI
CHI Advisors's Q2 2022 Portfolio in Review
As of Q2 2022, CHI Advisors held 28 positions worth $262M, up 11% from $235M the previous quarter. Its ten largest holdings account for 83% of the portfolio.
CHI Advisors deployed $49.5M of net new capital in Q2 2022, opening 6 new positions and adding to 13 existing holdings. Its largest new stake was Nkarta: 358,013 shares worth $4.41M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Oncorus, Inc., an estimated $67.9K trimmed.
- CHI Advisors's largest Q2 2022 buy was Nkarta: 358,013 shares worth $4.41M.
- CHI Advisors added most to Kezar Life Sciences in Q2 2022, an estimated $13.5M increase.
- CHI Advisors's biggest Q2 2022 reduction was Oncorus, Inc., cutting an estimated $67.9K.
- CHI Advisors's ten largest holdings make up 83% of its $262M portfolio in Q2 2022.
- CHI Advisors opened 6 new positions and closed 0 in Q2 2022.
- CHI Advisors's portfolio value rose 11% quarter-over-quarter to $262M.
Based on CHI Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.